Budesonide Suspension
Product Images NDC 55154-4849

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Budesonide (NDC 55154-4849). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

D8bb0fbc 3b34 45b1 91d1 Fd7b810873a4 00

Budesonide Inhalation Suspension 0.5 mg/2 mL label. The product contains 5 individually wrapped unit-dose vials, each with 2 mL of suspension. It is branded as Steri-Neb and intended for oral inhalation use only, not for injection. The label includes storage instructions, usage directions, warnings, and manufacturer details listing Cardinal Health as distributor.*

FDA Label Image

Chemical Structure For Budesonide (Image 1)

Chemical structure diagrams of Budesonide, showing molecular formula C25H34O6 and molecular weight 430.5.*

FDA Label Image

Figure 1: A 12 Week Trial In Pediatric Patients (Image 2)

A line graph showing mean change from baseline of nighttime asthma symptoms over 12 weeks. It compares placebo and three doses of Budesonide inhalation suspension (0.25 mg, 0.5 mg, and 1.0 mg once daily). The graph illustrates symptom improvement over time for each group with associated p-values indicating statistical significance at various doses.*

FDA Label Image

Figure 2: A 12-week Trail In Pediatric Patients (Image 3)

A line chart depicting the mean change from baseline in nighttime asthma symptoms over 12 weeks for three groups: placebo, 0.25 mg twice daily, and 0.5 mg twice daily. The x-axis shows time intervals from baseline to weeks 0-12, and the y-axis measures symptom change. Data points show symptom reduction over time for treatment groups compared to placebo, with p-values noted for significance at 0.022 and 0.021 for 0.25 mg and 0.5 mg doses respectively.*

FDA Label Image

Figure 3: A 12-week Trail In Pediatric (Image 4)

A line graph showing the mean change from baseline in nighttime asthma symptoms over a 12-week period. The graph compares placebo, 0.25 mg twice daily, and 0.5 mg twice daily doses of Budesonide respiratory suspension. The x-axis represents time intervals in weeks, while the y-axis shows the mean change from baseline. The graph includes p-values for various dose comparisons.*

FDA Label Image

1 (Image 5)

Illustration showing a hand holding an inhaler device with a cap removed and a dropper dispensing a liquid dose into the inhaler. It demonstrates the preparation or loading of a budesonide respiratory suspension inhaler prior to use.*

FDA Label Image

1 (Image 6)

An instructional illustration showing a person holding and preparing an inhalation suspension device, possibly demonstrating how to use the Budesonide respiratory inhalation suspension properly.*

FDA Label Image

1 (Image 7)

An instructional illustration showing the hand holding and using a respiratory suspension inhaler. It demonstrates how to position and operate the device for inhalation of Budesonide suspension.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.